CEBPZ and acute myeloid leukemia: Since AE expression is a recurrent clinical feature in CBF AML, the concept of targeting AE has been proposed and first strategies that specifically inactivate AE function have been reported (Barton et al, 2009; Wang et al, 2011; Wichmann et al, 2010).